Pfizer has discontinued the supply of FASIGYN (tinidazole) 500 mg tablet blister pack and SIMPLOTAN (tinidazole) 50… https://t.co/j44RNPsRSh
ASHM Report Back
Clinical posts from members and guests of the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM) from various international medical and scientific conferences on HIV, AIDS, viral hepatitis, and sexual health.
Highlights of Day 2 Glasgow 2016
Day 2 was amazing
The day started with the Lock lecture delivered by Julio Montaner from British Columbia. The overwhelming messages were:
Treatment as Prevention to prevent morbidity and mortality
ART is 100 % effective in preventing vertical transmission
While the end of the pandemic may be in sight, we need to be vigilant as there are problematic clusters of HIV emerging all the time and there is potential for the fire to be rekindled.
Jens Lundgren from Copenhagen provided a convincing argument for early vs deferred treatment but warned that CVS risk protection was not convincing with early treatment.
Cheryl Johnson from WHO Geneva provided a very insightful talk on the barriers to HIV testing and it is very apparent that this is the area that we need to improve upon if we are to meet the 90 90 90 target. The identification of the positive patients is the most important part of the cascade and we are still failing to identify them.
There was some controversy over HIV self testing and "At Home" STI screening but it was a suggestion to be able to test more people and reducing the stigma of having to go to a test centre and have the test. Also need to look at the accessibility of testing to patients - hours of opening and outreach centres.
Also discussed was differential ART delivery and the number of times per year that a stable patient needed to see a doctor.
There were a few Interactive cases which were very practical and could have been adapted to suit the practice of most of the clinicians in the audience.